- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.04.2025 | 317 | Xetra Newsboard | Das Instrument 2NH ES0105043006 NATURHOUSE HEALTH EO-,05 EQUITY wird cum Kapitalmassnahme gehandelt am 02.04.2025 und ex Kapitalmassnahme am 03.04.2025 The instrument 2NH ES0105043006 NATURHOUSE HEALTH... ► Artikel lesen | |
| SPRINT BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 08.01. | Sprint Bioscience AB: Sprint Biosciences upcoming activities | 84 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) summarizes below the company's upcoming meetings with potential partners and investors during the spring of 2025. In addition, the company will present at international scientific... ► Artikel lesen |
2 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,113 | +52,50 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 08.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 08.05.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 08.05.2025.ISIN NameGB00BYQ94H38 ONCIMMUNE... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 3,020 | -0,66 % | COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update | Repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Efforts continue to gain efficiencies through streamlining and cost cutting measures... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 44,260 | +3,22 % | Halozyme nach geplatzter Evotec-Übernahme - Aktie startet jetzt durch | Im November vergangenen Jahres hat US-Biotech-Unternehmen Halozyme Therapeutics mit der geplanten Übernahme von Evotec für Aufsehen gesorgt. Das Vorhaben ist zwar geplatzt, das Unternehmen befindet... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 1,778 | -3,40 % | AbCellera beginnt Phase-1-Studie für Wechseljahresbehandlung | ||
| GLOW LIFETECH | 0,033 | 0,00 % | Glow LifeTech Corp.: Glow Lifetech Reports 2024 Financials, Delivering Record Q4 Results with 46% Quarterly Revenue Growth and Strengthened Balance Sheet | Toronto, Ontario--(Newsfile Corp. - May 1, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the fourth quarter... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 209,60 | -6,72 % | Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results | HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results... ► Artikel lesen | |
| AVID BIOSERVICES | 12,100 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 05.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.02.2025ISIN NameCA75525M1095 RAZOR... ► Artikel lesen | |
| BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd.: BioLineRx Reports 2024 Financial Results and Provides Corporate Update | - Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases -
- Executed license... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 1,470 | -2,65 % | Whitehawk Therapeutics, Inc.: Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights | MORRISTOWN, N.J., May 8, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 1,510 | +8,63 % | Minerva Neurosciences, Inc: Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates | BURLINGTON, Mass., May 13, 2025(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,443 | +4,00 % | Applied Therapeutics Reports First Quarter 2025 Financial Results | - Company to present full 12-month clinical data and new topline 18-month and 24-month data from INSPIRE registrational Phase 3 trial of govorestat in CMT-SORD Deficiency at the Peripheral Nerve Society... ► Artikel lesen | |
| GEOVAX LABS | 2,685 | -100,00 % | Nitches, inc: Nitches Inc. Updates Shareholders on Amazon Integration, GovX Integration, and 2025 Growth Strategy for InTheZone Labs | LAS VEGAS, NV / ACCESSWIRE / December 18, 2024 / Nitches Inc. (OTC PINK:NICH) is pleased to share key updates regarding the recent strides made with its InTheZone Labs brand, highlighting successful... ► Artikel lesen | |
| OVID THERAPEUTICS | 0,266 | 0,00 % | Ovid Therapeutics GAAP EPS of -$0.14 in-line, revenue of $0.13M beats by $0.1M | ||
| COCRYSTAL | 1,280 | -5,88 % | Cocrystal Pharma, Inc. - 8-K, Current Report | ||
| PRECISION BIOSCIENCES | 4,140 | -7,17 % | PRECISION BIOSCIENCES INC - 10-Q, Quarterly Report |
Das Unternehmen SPRINT BIOSCIENCE AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,046 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPRINT BIOSCIENCE AB finden Sie auf Wallstreet Online.